Lilly posts sales below estimates
(Reuters) - U.S. drugmaker Eli Lilly and Co (LLY.N) reported lower-than-expected quarterly revenue on Thursday, hurt by disappointing sales of its cancer and diabetes drugs.
Lilly said it earned $728 million, or 68 cents per share, in the first quarter. It had profit of $1.55 billion, or $1.42 per share, a year earlier, when Lilly posted special gains from transferring rights to a diabetes drug.
Excluding special items, Lilly earned 70 cents per share, matching the average estimate of analysts, as compiled by Thomson Reuters I/B/E/S.
Revenue fell 16 percent to $4.68 billion while Wall Street expected $4.8 billion.
Lilly said it still expected earnings of $2.72 to $2.80 per share, excluding items, in full-year 2014.
(Corrects last paragraph to show 2014 profit outlook is unchanged rather than cut; removes reference to lowered outlook in headline and first paragraph)
(Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe)
- Study of smoking cancer patients fuels e-cigarette debate
- Islamic State closes in on Syrian town, refugees flood into Turkey |
- Exclusive: Iran seeks give and take on Islamic State militants, nuclear program
- Alibaba IPO ranks as world's biggest after additional shares sold
- Accused White House intruder is decorated Iraq war veteran